Dec 18, 2002
Genmab’s Financial Calendar for 2003

Dec 10, 2002
Genmab and Medarex Announce Filing of a Clinical Trial Application for HuMax-Inflam/MDX018

Dec 10, 2002
Last Day of Trading of Genmab’s Co-Ownership Interests (COIS) at the Frankfurt Stock Exchange

Dec 3, 2002
Genmab Announces HuMax-TAC Program

Nov 13, 2002
Strategy Update

Nov 11, 2002
Genmab’s HuMax-CD4 to be Tested in Cancer Patients

Nov 6, 2002
Genmab Announces Strategy Update Presentation

Oct 28, 2002
Genmab Announces HuMax-CD20 Program

Oct 14, 2002
Genmab Announces Financial Results for the Nine Months ended September 30, 2002

Sep 26, 2002
Grant of Warrants in Genmab A/S

Sep 24, 2002
HuMax-CD4 in Combination Therapy Not Effective in Rheumatoid Arthritis

Sep 19, 2002
US FDA approves Genmab’s IND HuMax-CD4 to treat psoriasis

Sep 10, 2002
Genmab to Delist from the Regulated Market at the Frankfurt Stock Exchange

Sep 10, 2002
Initial Accrual Complete in Genmab's HuMax-CD4 Phase II RA Study

Sep 4, 2002
Over 60% Achieve ACR20 with Genmab's HuMax-IL15

Aug 7, 2002
Timetable for Genmab's Delisting from Neuer Markt of the Frankfurt Stock Exchange

Aug 5, 2002
Genmab Appoints Rheumatology Specialist Jørgen Petersen as Medical Director

Jul 31, 2002
Genmab and Semaia Pharmaceuticals to Collaborate on Cancer Antibody Therapeutics

Jul 26, 2002
Genmab Applies to Delist From the Neuer Markt and the Frankfurt Stock Exchange

Jul 24, 2002
Genmab's Headquarters Moves To New Premises

Jul 15, 2002
Genmab Announces Financial Results for the Half Year Ended 30 June 2002

Jul 12, 2002
Genmab And JARI Pharmaceuticals BV Announce Antibody Therapeutics Collaboration

Jul 1, 2002
Genmab HuMax-IL15 Effective Against Psoriasis In Mouse Study

Jun 17, 2002
Genmab Publishes Offering Memorandum

Jun 11, 2002
Genmab to Present Humax-CD4 Phase II Safety Data at Eular HuMax-CD4 Safe and Well Tolerated in Clinical Studies

Jun 10, 2002
Genmab to Present at the Goldman Sachs, 23rd Annual Global Healthcare Conference in California

Jun 6, 2002
Roche and Genmab Announce Major Expansion of Antibody Collaboration

Jun 6, 2002
Capital Increase in Genmab A/S - Directed Offering Clarification of Number of Shares Issued

Jun 6, 2002
Capital Increase in Genmab A/S - Directed Offering

May 30, 2002
Genmab Completes Accrual in HuMax-IL15 Phase I/II Study

May 13, 2002
Genmab and ACE BioSciences Collaborate to Treat Infectious Disease

Apr 30, 2002
Genmab to Present at the JP Morgan H&Q 10th Annual Investing In Biotechnology Conference

Apr 29, 2002
Genmab Appoints VP Manufacturing

Apr 15, 2002
Genmab Announces Financial Results for the First Quarter Ended 31 March 2002

Apr 12, 2002
Psoriasis Patients In Genmab's HuMax-CD4 Phase II Trial Experience Long Lasting Effects

Apr 11, 2002
Genmab And Paradigm Therapeutics Announce Major Alliance On Discovery Targets For Human Antibody Therapeutics

Mar 11, 2002
Genmab And Bionomics to Co-Develop Human Antibodies for Angiogenesis Targets

Mar 7, 2002
Course of Annual General Meeting in Genmab A/S

Feb 21, 2002
Genmab's HuMax-CD4 Awarded Fast Track Status from FDA

Feb 20, 2002
Genmab to Present at the 2002 BIO CEO & Investor Conference in New York

Feb 20, 2002
Summoning of Ordinary General Meeting of Genmab A/S

Feb 11, 2002
Genmab Announces Year-end Financial Results

Jan 31, 2002
Corporate Action Timetable For Genmab A/S – 2002

Jan 23, 2002
Genmab To Acquire Land For Manufacturing Facility In Denmark

Jan 21, 2002
Dr. Ernst Schweizer Appointed Head of Business Development at Genmab

Jan 9, 2002
Oxford GlycoSciences, Medarex And Genmab Announce Comprehensive Campaign To Treat Breast Cancer

Jan 7, 2002
Genmab To Present At The 2002 JP Morgan H&Q Healthcare Conference In San Francisco